Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
baxdrostat + dapagliflozin
- Development stage
- Phase 3
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Baxdrostat + dapagliflozin is an investigational fixed-dose oral combination therapy currently in Phase 3 clinical trials for chronic kidney disease (CKD) and hypertension, as well as heart failure. Baxdrostat is a highly selective, oral small molecule inhibitor of aldosterone synthase (CYP11B2), which reduces aldosterone production without affecting cortisol synthesis. Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that lowers blood glucose and provides renal and cardiovascular protection. The combination aims to slow CKD progression and reduce cardiovascular events by targeting both aldosterone-mediated pathways and SGLT2-mediated glucose/sodium reabsorption[1][2][3][5][6].
- Other names
- baxdrostat/dapagliflozin
02
Targets
CYP11B2 (Cytochrome P450 11B2)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on baxdrostat + dapagliflozin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on baxdrostat + dapagliflozin.